Lincoln National Corp’s PDS Biotechnology PDSB Stock Holding History

Lincoln National Corp’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,647	Closed	-$76K	–	870
2021 Q1	$76K	Hold	16,647	–	–	﹤0.01%	789
2020 Q4	$36K	Hold	16,647	–	–	﹤0.01%	744
2020 Q3	$39K	Hold	16,647	–	–	﹤0.01%	668
2020 Q2	$33K	Buy	+16,647	New	+$18.5K	﹤0.01%	634

Other funds holding PDSB

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

EGI

EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lincoln National Corp's PDSB Position: Q2 2021 in Review

Lincoln National Corp sold out of PDS Biotechnology (PDSB) in Q2 2021, closing a stake of 16,647 shares — an estimated $76K sold.

Lincoln National Corp first reported a position in PDSB in Q2 2020 and held it in 4 quarters. The position peaked at $76K in Q1 2021. 46 funds tracked by Wall St. Rank hold PDSB as of Q2 2021.

Lincoln National Corp reported no remaining PDS Biotechnology position as of Q2 2021 after selling out during the quarter.
Lincoln National Corp sold 16,647 PDS Biotechnology shares in Q2 2021, an estimated $76K.
Lincoln National Corp first reported a position in PDS Biotechnology in Q2 2020 and held it in 4 quarters.
Lincoln National Corp's PDS Biotechnology position peaked at $76K in Q1 2021.
46 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2021.

Based on Lincoln National Corp's 13F filing for Q2 2021, filed 13 Aug 2021.